Nine-year survival outcome of neoadjuvant lapatinib with trastuzumab for HER2-positive breast cancer (NeoALTTO, BIG 1-06): final analysis of a multicentre, open-label, phase 3 randomised clinical trial.
Nuciforo, P., Townend, J., Saura, C., de Azumbaja, E., Hilbers, F., Manukyants, A., Werutsky, G., Bliss, J., Moebus, V., Colleoni, M., Aspitia, A.Moreno, Di Cosimo, S., Van dooren, V., Kroep, J., FerrVolume:
138
Journal:
European Journal of Cancer
DOI:
10.1016/S0959-8049(20)30560-8
Date:
October, 2020
File:
PDF, 72 KB
2020
File converter
More search results
More benefits 
